Cytokinetics (CYTK) was initiated by Citi analysts with a Buy rating, citing potential FDA approval for its lead asset ...

Citi initiated coverage of Cytokinetics (CYTK) with a Buy rating and $86 price target. The shares seem attractive at current levels, given the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK – Research Report) and ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is ...

Cytokinetics , Inc. (NASDAQ:CYTK), with a market capitalization of $5.65 billion, is approaching a pivotal moment in its journey to become a leading player in the cardiovascular therapeutics market.

Citi initiated coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and an $86.00 price target, representing significant upside from the current price of $46.17. The firm's analysts highlighted ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2025 it granted stock options to purchase an aggregate of 64,587 shares of common stock, 41,939 restricted stock units ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to ...

The FDA has followed the advice of its expert advisors and rejected Cytokinetics’ cardiac myosin activator omecamtiv mecarbil as a treatment for heart failure, saying the efficacy data for the ...

After hours: January 31 at 4:03:41 PM EST ...